Comment & Analysis

Mylan was desperate to do a defensive acquisition. This much is clear considering that it yesterday ...

Ibrance is the surprise hit of Pfizer’s post-Lipitor era, outperforming early expectations in its ...

The acquisition of Synergetics USA’s neuro portfolio from Valeant is a minuscule deal compared with ...

MedTech

EventAnalyzer

Therapeutic Focus

Market Moving Events

EP Vantage Interviews